Search details
1.
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Nature
; 625(7996): 778-787, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38081297
2.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 387(4): 310-320, 2022 07 28.
Article
in English
| MEDLINE | ID: mdl-35830649
3.
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Blood
; 141(22): 2727-2737, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-36857637
4.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood
; 140(11): 1229-1253, 2022 09 15.
Article
in English
| MEDLINE | ID: mdl-35653592
5.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood
; 139(3): 413-423, 2022 01 20.
Article
in English
| MEDLINE | ID: mdl-34570876
6.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood
; 140(21): 2193-2227, 2022 11 24.
Article
in English
| MEDLINE | ID: mdl-36001803
7.
Emerging immunotherapies in the Hodgkin lymphoma armamentarium.
Expert Opin Emerg Drugs
; : 1-13, 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38676917
8.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Br J Haematol
; 202(3): 525-529, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37217196
9.
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Blood
; 138(3): 213-220, 2021 07 22.
Article
in English
| MEDLINE | ID: mdl-34292324
10.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood
; 138(6): 427-438, 2021 08 12.
Article
in English
| MEDLINE | ID: mdl-33827139
11.
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
Blood
; 137(10): 1318-1326, 2021 03 11.
Article
in English
| MEDLINE | ID: mdl-32992341
12.
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.
Histopathology
; 82(7): 1105-1111, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36849712
13.
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Hematol Oncol
; 41 Suppl 1: 92-106, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37294966
14.
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Ann Hematol
; 102(1): 13-29, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36512081
15.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
; 21(11): 1118-1131, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37935098
16.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Am J Hematol
; 98(3): 464-471, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36629030
17.
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Oncologist
; 27(10): 864-873, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35948003
18.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Article
in English
| MEDLINE | ID: mdl-31945149
19.
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
Blood
; 135(26): 2365-2374, 2020 06 25.
Article
in English
| MEDLINE | ID: mdl-32211877
20.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
J Natl Compr Canc Netw
; 20(4): 322-334, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35390768